Health Decisions Selects OmniComm Systems' TrialMaster EDC Solution

Health Decisions Selects OmniComm Systems' TrialMaster EDC Solution
Adaptive CRO Implements OmniComm's eClinical Solution to Drive Operational Efficiencies
FORT LAUDERDALE, FL--(Marketwire - May 13, 2010) -  OmniComm Systems, Inc. (OTCBB: OMCM), a global provider of eClinical solutions, announced that Health Decisions, a Contract Research Organization (CRO) specializing in high-efficiency adaptive clinical trials, recently signed an agreement to utilize OmniComm's TrialMaster eClinical products platform.

Health Decisions raises standards of efficiency, quality, and success in the development of pharmaceutical products and medical devices. The company's unique trial management methodology, coined Agile Clinical Development, combines adaptive design with adaptive operations to significantly accelerate timelines, optimize resource allocation, improve data quality, and maximize both the return on investment and net present value of its sponsors' clinical projects. With more than twenty years of experience in all major therapeutic areas, Health Decisions has provided its services to leading global biotech and pharmaceutical companies, managing Phase I - IV trials, registration studies, 510(k) submissions, and PMA trials. Health Decisions is headquartered in Durham, North Carolina and operates studies globally.

Health Decisions selected TrialMaster for its advanced technology, its ability to deliver cost-effective operational efficiencies, and its interoperability with Health Decisions' proprietary processes and software including Adaptive Monitoring, Adaptive Randomization, and the company's comprehensive CTMS. This integration amplifies the value of OmniComm software to Health Decisions by enabling rapid study build with flexible data collection and workflow capabilities. Total cost of ownership was also a key consideration in the CRO's decision to deploy OmniComm solutions.

"OmniComm is one of the very few eClinical solutions providers capable of delivering on the high standards of data collection and reporting that, when combined with Health Decisions' systems, enable the high degree of transparency and control that our sponsors have come to expect," said Michael Rosenberg, MD, MPH, chief executive officer at Health Decisions. "By adding the OmniComm system to our catalog of data collection options, Health Decisions can now ensure even greater study efficiency from the initial point of patient contact through regulatory submission. We look forward to building on and expanding our offering with OmniComm's superior EDC solutions."

"The partnering of Health Decisions and OmniComm Systems makes perfect sense," says Stephen Johnson, chief operating officer at OmniComm Systems. "Health Decisions has extensive experience enabling rapid information flows, as well as the technology infrastructure necessary to support real-time data collection, which dovetails nicely with EDC. We look forward to offering our collective customers an integrated solution to meet their complex data collection needs."

About Health Decisions
Health Decisions is a global clinical research organization (CRO) focused on improving the efficiency of clinical development Agile Clinical Development -- a strategic combination of adaptive design and adaptive operations -- Health Decisions allows a continuous refinements approach that optimizes clinical research from design to the detailed day-to-day management, enabling sponsors to make earlier, better informed decisions on all levels. For more information, please visit the company's website at www.HealthDec.com.

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to large-scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT: Stephen Johnson at: + 1 954-377-1726

CONTACT:
Mark Rice
OmniComm Systems, Inc.
858-259-2365
[email protected]

Rick Farris
Health Decisions Inc.
919-967-1111 Ext 298
[email protected]

Gary Nash
CEOcast, Inc. for OmniComm
212-732-4300
[email protected]

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.